Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 November 2014Website:
http://www.coherus.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 20 Jun 2024 22:33:50 GMTDividend
Analysts recommendations
Institutional Ownership
CHRS Latest News
CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale.
The biotech unveiled its latest set of quarterly and annual results. Its revenue for the former period rose sharply, but missed analyst expectations -- as did its bottom-line result.
Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript
Following the closing of its recently announced divestiture of its noncore ophthalmology business, Coherus will prepay a huge chunk of its term loan with Pharmakon. The move will reduce interest expenses by 70%, allowing Coherus to hone its focus on its oncology products.
Coherus BioSciences stock initially jumped after the announcement of a deal to sell Cimerli to Sandoz. However, shares are now sinking with investors reminded of the financial challenges that Coherus faces.
Coherus announced a $170 million deal to divest Cimerli to Sandoz Group. The company is paying down debt and refocusing on its core oncology business.
Coherus BioSciences (NASDAQ: CHRS ) stock is taking off on Monday after the biopharmaceutical company announced a $170 million divestment. Coherus BioSciences is selling its CIMERLI ophthalmology franchise to Sandoz (OTCMKTS:SDZNY) for an upfront payment of $170 million.
After months of delays following an FDA review of its Udenyca OnBody biologics license application, Coherus has finally received FDA approval for the product. Coherus is planning commercial availability of Udenyca OnBody for the first quarter of 2024.
The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.
Coherus BioSciences (NASDAQ:CHRS) shares gained more than 20% in early trade on Wednesday after it revealed that the United States Food and Drug Administration (FDA) has approved UDENYCA ONBODY, the company's on-body injector presentation of UDENYCA (pegfilgrastim-cbqv). Pegfilgrastim or biosimilar drugs are administered to cancer patients the day after they complete chemotherapy to decrease the risk of infection.
- 1(current)
- 2
What type of business is Coherus BioSciences?
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
What sector is Coherus BioSciences in?
Coherus BioSciences is in the Healthcare sector
What industry is Coherus BioSciences in?
Coherus BioSciences is in the Biotechnology industry
What country is Coherus BioSciences from?
Coherus BioSciences is headquartered in United States
When did Coherus BioSciences go public?
Coherus BioSciences initial public offering (IPO) was on 06 November 2014
What is Coherus BioSciences website?
https://www.coherus.com
Is Coherus BioSciences in the S&P 500?
No, Coherus BioSciences is not included in the S&P 500 index
Is Coherus BioSciences in the NASDAQ 100?
No, Coherus BioSciences is not included in the NASDAQ 100 index
Is Coherus BioSciences in the Dow Jones?
No, Coherus BioSciences is not included in the Dow Jones index
When does Coherus BioSciences report earnings?
The next expected earnings date for Coherus BioSciences is 02 August 2024